IPO

Supriya Lifescience IPO

Mainboard

Pharmaceuticals & Drugs

Listed On: Dec 28, 2021 at ₹ 421.00(NSE)

₹ 14796 /54 Shares

Check Allotment

16 Dec, 2021

Open Date

20 Dec, 2021

Close Date

24 Dec, 2021

Allotment Date

28 Dec, 2021

Listing Date
Price Summary

Last Closing

737.85 (169.29%)

52 Week High

842.00

52 Week Low

556.15

Last Update

19-Dec-2025 3:30 PM
IPO Issue Details
  • Issue Price ₹265-274 per equity share
  • Face Value ₹2 Per Equity Share 
  • Issue Price Total 700 Crores : Fresh Issue: ₹200 Cr + Offer for Sale : ₹500 Cr
  • Listing at BSE, NSE
  • List Price 421.00(NSE)
  • Listing Date 2021-12-28
  • Lead Manager ICICI Securities Limited, and Axis Capital Limited
  • Registrar Link Intime India Private Limited
IPO Details
  • Retail Portion 10% (Number of Retail Applications : 47,300 Approx)
IPO Documents
DRHP
RHP
IPO Details


The IPO of is priced at ₹265-274 per equity share, which has a face value of ₹2 Per Equity Share  each, IPO bidding starts from Dec 16, 2021 and ends on Dec 20, 2021. The allotment for IPO will be finalized on Dec 24, 2021. IPO will be listed on BSE, NSE, with a tentative listing date fixed as Dec 28, 2021. The company shall list its equity shares on the BSE, NSE. Link Intime India Private Limited is the registrar of the issue.

The book-running lead manager for the IPO is/are ICICI Securities Limited, and Axis Capital Limited.


The IPO sets its price band at 265-274 for each share. A single application for Supriya Lifescience IPO must contain at least 54 shares.

Read More
IPO Subscription Analysis And Details
Retail
55.75x
QIB
31.83x
NII
161.22x
Total
71.46x
As on QIB NII Retail Total
Shares Offered / Reserved 76,64,232 38,32,116 25,54,745 140,51,093
Day 1 16-12-21 05:00 PM
0.00 x 0.66 11.84 x 2.33 x
Day 2 17-12-21 05:00 PM
0.53 x 2.90 25.37 x 5.70 x
Day 3 20-12-21 05:00 PM
31.83 x 161.22 55.75 x 71.46 x
Total No of Applications
2354306
Subscription on the basis of Applications
49.76
Valuations
Earnings Per Share (EPS) ₹15.39/-
P/E Ratio 17.81
RoNW 46.04%
Net Asset Value (NAV) - As on 31.03.21 ₹45.76
Company Financials
In Crs.
In Cr.
31-Mar-21 31-Mar-20 31-Mar-19
Assets 445.82 336.40 253.05
Revenue 396.22 322.71 285.86
Profit After Tax 123.82 73.37 39.42
About Company

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume.In Fiscal 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company's manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.

Read More
- Promoter(s)

Satish Waman Wagh

Pre Issue Share Holding : 99.98%

Post Issue Share Holding : 68.24%

IPO - Issue Objectives
1

Funding capital expenditure requirements of their Company

2

Repayment and/ or pre-payment, in full or part, of certain borrowings availed by their Company

3

General corporate purposes

IPO - Anchor Investors

Supriya Lifescience mobilises Rs 315 crore from anchor investors ahead of IPO

Marquee investors who participated and invested in the company were Dovetail India Fund, Cohesion MK Best Ideas, Hornbill Orchid India Fund, Volrado Venture Partners Fund, Optimix Wholesale Global, and Societe Generale.

Among domestic investors, Nippon Life, Aditya Birla Sun Life Insurance, Abakkus Growth Fund, and Reliance General Insurance also put in money in Supriya Lifescience.

IPO - Peers Comparison
P/B Ratio P/E Ratio RoNW Revenue(in Cr.)
Supriya Lifescience 5.99 17.81 46.04% 396.22
Solara Active Pharma 2.48 20.33 12.22% 1,645.29
Neuland Lab 2.75 30.26 9.07% 953.01
Aarti Drugs 6.12 26.54 23.06% 1,921.31